Compare HIPO & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | VTYX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.6M | 713.6M |
| IPO Year | N/A | 2021 |
| Metric | HIPO | VTYX |
|---|---|---|
| Price | $31.51 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $37.50 | $14.60 |
| AVG Volume (30 Days) | 183.8K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $450,000,000.00 | N/A |
| Revenue This Year | $29.21 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | ★ 34.41 | N/A |
| 52 Week Low | $19.92 | $0.78 |
| 52 Week High | $38.98 | $10.55 |
| Indicator | HIPO | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 56.53 |
| Support Level | $30.31 | $7.59 |
| Resistance Level | $31.49 | $8.52 |
| Average True Range (ATR) | 0.98 | 0.57 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 83.89 | 77.84 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.